Clinical trial

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

NCT03511196

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-09-17

PhaseEARLY_PHASE1

Study timeline

Study start (actual)2018-09-17Date precision: day

Registry last updated2025-12-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Stage IV Prostate Cancerunresolved

Advanced Prostate Cancerunresolved

Adenocarcinoma of the Prostateunresolved

Interventions

Adaptive Androgen Deprivation Therapy (ADT)DRUG

AbirateroneDRUG · verified · RxNorm: abiraterone

PrednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

Mapped research locations

TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03511196 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.